BGM Group Ltd. (NASDAQ:BGM) Short Interest Update

BGM Group Ltd. (NASDAQ:BGM) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 314,375 shares, a growth of 76.3% from the June 30th total of 178,275 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 748,276 shares, the days-to-cover ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of BGM Group in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of BGM Group

A number of hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new position in BGM Group in the second quarter worth $218,000. Mariner LLC acquired a new stake in BGM Group during the third quarter valued at approximately $267,000. Finally, Geode Capital Management LLC bought a new stake in shares of BGM Group in the 2nd quarter valued at approximately $412,000.

BGM Group Stock Up 2.6%

Shares of BGM stock traded up $0.01 during trading hours on Friday, reaching $0.28. 20,547 shares of the company’s stock were exchanged, compared to its average volume of 301,677. BGM Group has a fifty-two week low of $0.25 and a fifty-two week high of $11.80. The business has a fifty day moving average price of $0.33 and a 200-day moving average price of $0.89.

BGM Group (NASDAQ:BGM) last announced its quarterly earnings data on Tuesday, July 21st. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $11.80 million for the quarter.

About BGM Group

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.